You were invited to our Q4/2024 Townhall, where we explored our future organization based on what has been agreed upon until then. Updates from our Leadership Team included insights from the PH Strategy Summit, which did initiate discussions on our financials and the strategic mid- and long-term outcomes for Pharma. Additionally, we reflected on the results of the Ownership Pulse (formerly known as Employee Voice), discussed further considerations, and allocated time for a Q&A session. This token serves as appreciation for and proof of your participation. POAP dropped for Bayer DT&IT Pharma Design by stefankai with Canva POAP Terms & Conditions: https://bayer.com/poap Bayer IT POAP Collection: https://collections.poap.xyz/bayer-it/

Thank you for attending today's DT & IT Pharma Townhall! In today's meeting, we delved deeper into the successful launch of the Pharma Control Tower (go/PHCT), which serves as a central entry point for all your needs related to financial, operational stability, and governance for your applications, portfolios, and functions. Additionally, we shared some updates on the rollout of MyGenAssist at Pharma, highlighting our crucial role as key ambassadors. This past year has underscored the accelerated pace of innovation, with GenAI standing out as a prime example of the agility needed to proactively evolve our skill sets. Furthermore, we collectively reviewed our key priorities for 2024 and provided updates on our DSO learning journey. In summary: ///// PH Control Tower ///// Business priorities per department ///// MyGenAssist roll-out PH ///// DSO Champions update Bayer terms & conditions apply: https://www.bayer.com/en/poap-tc

For the participation on the CID EMEA LATAM Team Meeting 2024 in Barcelona, Spain

Another DSO Open MIC session is in the books! Whether you have attended the morning or afternoon session, without a doubt you have contributed significantly to the success of today's event. These sessions are a space for open exchanges about ongoing topics around DSO and an opportunity to share, ask questions, provide feedback, or just listen. Everyone is invited to attend, participation is voluntary, and the sessions will not be recorded. Bayer terms & conditions apply: https://www.bayer.com/en/poap-tc

Endometriosis is a chronic, estrogen-dependent condition where tissue similar to the lining inside the uterus, known as endometrium, grows outside the uterine cavity. This aberrant tissue growth can occur on the ovaries, fallopian tubes, pelvic lining, and other areas, leading to pain, infertility, and other complications. It was first clearly described in 1860, but symptoms consistent with the condition were mentioned in texts 4000 years ago. Epidemiologically, endometriosis affects 10% of women of reproductive age, 176 million women worldwide. The condition is most commonly diagnosed in women in their 30s and 40s, although it can occur in any female post-puberty. Management of endometriosis includes a combination of pharmacological and surgical options. Medications like nonsteroidal anti-inflammatory drugs (NSAIDs), hormonal therapies, and gonadotropin-releasing hormone (GnRH) analogs are used to manage symptoms. In more severe cases, surgical interventions, including laparoscopy, may be necessary to remove endometrial lesions and improve fertility. The impact of endometriosis is multifaceted, affecting physical, mental health and quality of life. The condition also imposes economic burdens due to healthcare costs and lost productivity. Psychologically, it can lead to anxiety, depression, and other emotional stressors, emphasizing the need for comprehensive care and support for affected individuals. https://en.wikipedia.org/wiki/Endometriosis Art&Text🫶ChatGPT.